Barriers to Confirmatory Trial Enrollment Present Unique Hurdles for Accelerated Approvals
February 8th 2023Despite the favorable comments and interest in clinical trials, the objective fact is that a distressingly low percentage of patients with cancer, in the range of 2% to 4%, are enrolled in clinical investigative efforts.
Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers
January 10th 2023Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.
Selinexor/Ruxolitinib Combo Reduces Spleen Volume in Myelofibrosis
The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.
Effective Communication on HPV Vaccination Benefits Is Needed
November 29th 2022Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.